

January 26, 2023



D.C. Update: New NASADAD Fact Sheet, SAMHSA's 19th Prevention Day, FDA Joint Public Advisory Committee Meeting to Discuss Proposed OTC Naloxone, and More.

Visit our Website



Meet the Member

Deirdre Calvert, SSA of Massachusetts, joins NASADAD Board of Directors as Director of Region I



We are excited to announce that Ms. Deirdre Calvert, SSA in Massachusetts, is joining the NASADAD Board of Directors as Regional Director I. Congratulations Deirdre!


Deirdre Calvert has been the Director of the Massachusetts Department of Public Health, Bureau of Substance Addiction Services (BSAS) since April 2019. In that role, Director Calvert is the designated Single State Authority (SSA) responsible for licensing and regulating all Massachusetts treatment programs for substance use disorders which encompasses over 500 providers statewide supporting prevention, intervention, treatment, and recovery from addiction. Prior to BSAS, Director Calvert worked for more than 25 years as a clinical director and social worker in the Massachusetts substance use disorder system. She is also an adjunct professor at Boston University School of Social Work and School of Public Health. Director Calvert holds an MSW (master's in social work) from Boston University and is a Licensed Independent Clinical Social Worker (LICSW).

Welcome Deirdre!

NASADAD News

Updated Fact Sheet: Reauthorization of the Substance Use Prevention, Treatment, and Recovery Services (SUPTRS) Block Grant

NASADAD is pleased to share an updated fact sheet on Reauthorization of the Substance Use Prevention, Treatment, and Recovery Services (SUPTRS) Block Grant (formerly the Substance Abuse Prevention and Treatment [SAPT] Block Grant), housed within the Substance Abuse and Mental Health Services Administration (SAMHSA).



On December 29, 2022, President Joe Biden signed the Consolidated Appropriations Act, 2023 ([H.R. 2617](#)) now, [Public Law No: 117-164](#). This large omnibus bill included fiscal year 2023 appropriations and provisions reauthorizing certain federal programs through fiscal year 2027, including the SUPTRS Block Grant. The reauthorization of the Block Grant included new reporting requirements, language changes, and more.

To see a side-by-side analysis of the Public Law compared to the legislation proposed in the House of Representatives and Senate, visit NASADAD's webpage [here](#).

Around the Agencies

SAMHSA's 19th Prevention Day: January 30, 2023



The Substance Abuse and Mental Health Services Administration (SAMHSA), in conjunction with the Community Anti-Drug Coalitions of America (CADCA) National Leadership Forum, is hosting the [19th Prevention Day](#) on Monday, January 30, 2023, at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland. Prevention Day is a free national event that aims to share new and innovative approaches to substance use disorder (SUD) prevention and mental health and provides opportunities to connect with peers. Participants have the chance to meet SAMHSA representatives and get exclusive access to SAMHSA's innovative "Prevention Action Center," which is an interactive learning hub with exhibits and resources on the latest prevention trends and major health communication initiatives and campaigns. Continuing education credits are provided for all registered Prevention Day attendees through coordination with CADCA.

Attendees must register [here](#).

The full agenda can be found [here](#).

CDC Accepting Applications for the Public Health Associate Program



The Centers for Disease Control and Prevention (CDC) is accepting applications for the [Public Health Associate Program \(PHAP\)](#). PHAP is a paid two-year training program for recent college graduates pursuing public health careers. The program aims to offer early-career public health professionals with hands-on, real-life experience in the day-to-day operations of public health programs by assigning associates to State, tribal, local, and territorial public health agencies; nongovernmental organizations; public health institutes and associations; community-based organizations; and academic institutions. Applications are due by January 30, 2023.

The USAJobs job posting can be found [here](#).

New OMH and ASPE Data Brief: Addressing Substance Use and Social Needs of People of Color with Substance Use Disorders

The Department of Health and Human Services' (HHS) Office of Minority Health (OMH) and Office of the Assistant Secretary for Planning and Evaluation (ASPE) released an issue brief on [Addressing Substance Use and Social Needs of People of Color with Substance Use Disorders](#). This data brief describes findings from a joint study on substance use disorder (SUD) treatment disparities among people of color and SUD

treatment approaches by examining the experiences and practices of SUD treatment providers and their human services partners serving people of color. Key findings from the brief include:

- “Treatment providers highlighted several practices that promoted active and positive participation in their programs by people of color:
- Incorporate the community’s cultural values into organizational structures and treatment models.
- Engage the community in designing programs and services and hire staff that reflect the community.
- Address the comprehensive health, social, and economic needs of participants.
- Incorporate harm reduction services and healing-centered approaches in the continuum of care.
- Providers described several constraints when serving communities of color:
- Structural barriers such as poverty, racism, and differential access, which significantly impede meeting clients’ social and economic needs.
- Challenges maintaining program staff with the appropriate language and cultural skills.
- A complex patchwork of funding streams.
- A lack of data and limited internal capacity for data analysis and program evaluation.”

The brief can be downloaded in full, [here](#).

FDA Announces Joint Public Advisory Committee Meeting to Discuss Proposed OTC Naloxone



The Food and Drug Administration (FDA) recently issued a [Federal Register notice](#) announcing a joint public advisory committee meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss a proposal for over the counter (OTC) naloxone. The Committee is scheduled to meet on February 15, 2023, to review the supplemental new drug application for an OTC version of naloxone nasal spray, which would be the first of its kind available in the United States. This notice follows the [FDA’s November 2022 press release’s](#) finding that certain naloxone products may be “approvable as safe and effective for nonprescription use”. FDA has established a [public docket](#) and is requesting public comment on the proposal by February 14, 2023. The meeting can be viewed and will be recorded through an online teleconferencing platform.

The FDA’s press release announcing the joint public advisory committee meeting and additional details on submitting public comments and participating in the meeting can be found [here](#).

New SAMHSA Resource: Expanding Access to and Use of Behavioral Health Services for People At Risk For or Experiencing Homelessness

The Substance Abuse and Mental Health Services Administration (SAMHSA) released a new resource on [Expanding Access to and Use of Behavioral Health Services for People At Risk for or Experiencing Homelessness](#). According to the press release, this guide uniquely highlights strategies for mental health and substance use disorder (SUD) services and housing providers to engage with people currently experiencing or at risk for homelessness to initiate use of mental health and SUD treatment, as well as other support services, while the individual is waiting for housing placement. The guide covers five programs with proven success in improving mental health and SUD outcomes for individuals experiencing homelessness. In addition to detailing and providing evidence of the interventions’ success, the guide also offers implementation strategies for providers, staff, and organizations- with four real-life case examples across the country.

The Mental Health Technology Transfer Center (MHTTC) Network, in collaboration with SAMHSA and Abt Associates, will host a [webinar](#) highlighting the findings from this new guide. This no-cost webinar will be offered on February 2, 2023, at 2:00 pm (ET). Registration is required

Research Roundup

NIDA Study Finds that Overdose Deaths Involving Buprenorphine did not Proportionally Increase with new Flexibilities in Prescribing

Researchers at the National Institute on Drug Abuse (NIDA) and the Centers for Disease Control and Prevention (CDC) published a [study](#) in the Journal of the American Medical Association (JAMA) Network Open on the effects of expanding access to medication for opioid use disorder (MOUD) on opioid overdose deaths. The study found that the proportion of opioid overdose deaths involving buprenorphine did not increase in the months after the COVID-19 prescribing flexibilities were put in place. Primary findings from the study include:

- Between July 2019 and June 2021, there were 1,955 buprenorphine-involved overdose deaths, which equates to 2.2% of the 89,111 total overdose deaths and 2.6% of the 74,474 opioid-involved overdose deaths in the CDC's State Unintentional Drug Overdose Reporting System (SUDORS) dataset for that period.
- Between April 2020 and June 2021, when buprenorphine prescribing flexibilities were put in place, monthly opioid-involved overdose deaths increased overall; however, the proportion of those deaths involving buprenorphine did not increase.
- 92.7% of buprenorphine-involved overdose deaths involved at least one other drug.
- Compared with other opioid-involved overdose deaths, buprenorphine-involved overdose deaths were more likely to involve prescription medications but less likely to involve illicitly manufactured fentanyl.
- Regardless of the drugs involved, most people who died of an opioid-involved overdose, including buprenorphine, had no evidence of current treatment for substance use disorders (SUD).

The study's findings call for more equitable access to MOUD and greater flexibility in prescribing as critical to the nation's response to the overdose crisis.

NIDA's news release announcing the study results can be found [here](#).

Webinars to Watch

COSSAP Webinar: Best Practices in Implementing Peer Recovery Support Services in Law Enforcement Settings



The Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP), in collaboration with Altarum, will host a [webinar](#) on Best Practices in Implementing Peer Recovery Support Services in Law Enforcement Settings. This no-cost webinar will be offered on January 31, 2023, at 1:00 pm (ET). The webinar will explore effective implementations of peer recovery support service (PRSS) within two law enforcement deflection initiatives in Winthrop and Plymouth, Massachusetts. The webinar will highlight the unique role peer providers play in addressing opioid, stimulant, and other substance use disorders (SUD), the power of lived experience in PRSS, and evidence-supported best practices for achieving positive outcomes in peer programming. Registration is required.

Bureau of Primary Health Care Behavioral Health Technical Assistance Webinar: Reentry Recovery Services to Improve Health and Reduce Recidivism and Overdoses Among Formerly Incarcerated Individuals

The Bureau of Primary Health Care Behavioral Health Technical Assistance (BPHC-BH TA) is hosting a [webinar](#) on Reentry Recovery Services to Improve Health and Reduce

Recidivism and Overdoses Among Formerly Incarcerated Individuals. This no-cost webinar is offered on February 1, 2023, at 1:00 pm (ET). The webinar will highlight the steps taken by Fairfax County, Virginia, to provide successful transition from incarceration to reentry to reduce recidivism rates, improve health outcomes, and reduce drug overdose. Registration is required.

NASADAD | 202-293-0090 | [nasadad.org](https://www.nasadad.org)